Welcome Letter Save the date #ADPD2027 |

Striving for a better future for all those affected by
neurodegenerative diseases

AD/PD™ focuses on basic science and translational and clinical research to bring you:

Mechanisms

Neurodegeneration, protein aggregation, and the fundamental pathways of disease.

Clinical Trials

Phase I–III trial presentation and the future of pharmacological intervention.

Diagnostics

Fluid markers, neuroimaging, and the advancement of early detection.

Drug Discovery

Translating chemical leads into viable therapeutic strategies.

New Therapies

Gene therapy, immunotherapy, and regenerative medicine breakthroughs.

Prevention

Lifestyle, risk factors, and the proactive shield against decline.

Alzeimer's and Parkinson's Diseases and Related Disorders

AD/PD™ Session Spotlight

ABSTRACT SUBMISSION

Submit your abstract and share your findings with our international community.

ABSTRACT SUBMISSION

AD/PD™ Education on UNLOK

Join the world's leading community of neurodegenerative research professionals.

ACCESS PORTAL
EDUCATION PORTAL

COMMITTEE

View the full list of international experts guiding the AD/PD™ Conference.

LEARN MORE

Organizing Committee

Meet the leaders shaping AD/PD™

Abraham Fisher, Israel, President

Ezio Giacobini, Switzerland, Executive Organizer

Gabriel Gold, Switzerland, Executive Organizer

Cynthia Lemere, USA, Executive Organizer

Henrietta Nielsen, Sweden, Executive Organizer

Roger M. Nitsch, Switzerland, Executive Organizer

Tamara Shiner, Israel, Executive Organizer

Manfred Windisch, Austria, Executive Organizer

Committee & Advisory Board

Cutting-Edge Science at
the Heart of AD/PD™ 2027

AD/PD™ 2027 brings together the world’s brightest scientific minds to share the very latest breakthroughs across the full spectrum of Alzheimer’s and Parkinson’s research. From mechanistic insights to translational therapies, the programme is curated to ignite discovery and inspire the next generation of neuroscientists.

Whether presenting pioneering research, engaging with global thought leaders, or exploring the commercial landscape of neurodegeneration, AD/PD™ 2027 in Barcelona provides the ideal environment for meaningful scientific exchange.

Explore the Program
Statistics from AD/PD™ 2026:
0

Participants

0 +

Countries registered

0

Abstracts submitted

0 Days

Of scientific excellence

Voices from the AD/PD™ Community

Quotes from researchers, clinicians, and innovators who have experienced
AD/PD™ first-hand.

"A big THANK YOU for an amazing week in Copenhagen. I came home completely exhausted in a wonderful way, full of impressions. This meeting contained truly amazing and very thought-provoking presentations. To me, it felt like the best meeting on neurodegenerative diseases I have ever been to. It is clear to me that we have entered a new and very positive phase, and that the speed of discovery and progress is higher than ever with quite innovative approaches."

Henrik Zetterberg, University of Gothenburg

This was one of the most exciting meetings I have been in a long time. The program was exceptional and so many advancements. I enjoyed enormously the fireside chat discussion and the different perspectives. Congratulations to you and the team for a perfect meeting.

Marco Prado, University of Western Ontario

The conference has grown so much, because the field has grown so much. The conference this year is one of the most exciting I’ve been to.

Fiona Ducotterd, University College London

Thank you for another amazing conference! Having been in the field since 1988, it is quite extraordinary where we are today and AD/PD has played a seminal role and will continue to do so.

Rhoda Au, Boston University

The meeting is really excellent. I have heard so many positive comments from many attendees. A very positive aspect of the AD/PD conference is that the atmosphere is very friendly and there are many chances to meet people and have lively discussions.

Ole Isacson, McLean Hospital / Harvard Medical School

AD/PD™ Education on UNLOK

The Online Community for all Neurodegenerative Disease Professionals

Click here